南非：着力成为非洲生物技术中心

南非是非洲经济最发达的国家,也是非盟科技领域的领头羊,但南非生物技术发展起步相对较晚。2002年南非颁布了《南非国家生物技术战略》,通过修订和完善相关法律法规,建立区域创新中心,培养高水平人才,加强知识产权保护和成果转化,以及重视国际合作等措施,推进生物科技及产业发展。南非是目前唯一允许转基因作物商业化种植的非洲国家,6个艾滋病候选疫苗已进入临床试验,在生物采矿和冶炼黄金,生物能源以及生物环保方面也取得了重要成就。     

中意生物安全国际研讨会通知

为了加强生物安全管理和促进生物技术产业的健康发展 ,中国和一些国家、地区及相关国际组织先后制定了一系列的有关指导原则、安全性评价体系、技术标准及安全法规等 ,同时各国之间也积极开展了相关知识讲座和国际交流 ,为生物技术领域的良性发展提供了相互借鉴的经验。作为中意双边政府间合作的一项重要内容 ,中国科技部生物工程开发中心、北京生物技术和新医药产业促进中心与意大利国际农业研究所、意大利驻华使馆科技处联合于 2 0 0 1年 9月 9— 14日在中国北京举办“中意生物安全国际研讨会及讲座”。大会将邀请生物安全研究及管理领域…     

国内外生物技术安全管理机制

综述了国内外生物安全管理机制,特别是生物技术安全管理机构和运行方式,分别就国际组织、美洲、欧洲和亚洲国家以及中国的有关制定、颁布和实施生物安全管理的作法和机构进行讨论,重点介绍了我国现有的生物技术安全管理办法、法则及其运行机制,最后提出了我国未来生物技术安全管理办法发展的重点。     

生物安全时代:新生物科技变革与国家安全治理*

科技进步改进了人类对天然生物危害因子的操控能力,在诱发新的生物安全危害形态的同时,也赋予了生物安全客体的源头难以追溯性、生物安全主体的多元性、生物安全危害演变机理的复杂性等特点。生物安全在很大程度上体现了非传统安全的非传统特点。随着生物科技与生物安全在推动人类社会发展进程的作用日益显著,21世纪或将成为生物安全的时代。新一轮生物科技变革及其与人类社会互动衍生的生物安全问题,已经逐渐触及人类安全观念和现代文明的内源性危机或挑战。全面提升国家生物安全能力、优化国家生物安全治理,不仅是世界各国的战略选择,也是对人类科技文明与政治文明的新探索。     

生物安全时代:新生物科技变革与国家安全治理*

科技进步改进了人类对天然生物危害因子的操控能力,在诱发新的生物安全危害形态的同时,也赋予了生物安全客体的源头难以追溯性、生物安全主体的多元性、生物安全危害演变机理的复杂性等特点。生物安全在很大程度上体现了非传统安全的非传统特点。随着生物科技与生物安全在推动人类社会发展进程的作用日益显著,21世纪或将成为生物安全的时代。新一轮生物科技变革及其与人类社会互动衍生的生物安全问题,已经逐渐触及人类安全观念和现代文明的内源性危机或挑战。全面提升国家生物安全能力、优化国家生物安全治理,不仅是世界各国的战略选择,也是对人类科技文明与政治文明的新探索。     

新西兰生物科技及产业现状及特点

新西兰生物产业的规模并不十分引人注目,但却是新西兰经济中不可忽视的组成部分,其生物科技方面的优势领域主要是农业生物技术和生物医学两方面,例如大型动植物、生物安全、环境保护、神经科学、心血管疾病、结核与哮喘、糖尿病和癌症等研究领域。新西兰政府十分重视生物科技和产业的发展,在其2002年颁布的《创新增长框架》计划中,将生物技术列为未来的三大经济增长支柱之一,将加大对生物科技和产业的投入作为新西兰向高技术经济转型的重要举措。     

总体国家安全观下合成生物学风险和应对策略研究*

合成生物学是近年来兴起的一门兼材料学、医学和信息学等学科特性的交叉学科,在促进医学进步和科技转化应用的同时,也在总体国家安全内涵中被赋予了特殊的重要地位。如何在新时期应对错综复杂的安全形势和严峻挑战,是世界各国和国际社会所面临的科技治理和生物安全的重要命题。重点介绍合成生物技术相关生物武器威胁、生物恐怖威胁、生物安全国际公约条例、生物安全伦理治理框架,总结近年来合成生物技术领域生物安全风险相关问题,提出合成生物学安全风险应对策略和国家总体安全观下科技发展建议。     

基于文献计量的全球生物技术研究现状与发展趋势分析

采用文献计量分析方法,分析了全球生物技术研究领域的发展现状和趋势及其对中国生物技术研究发展的启示。研究结果表明:2019年我国在生物技术文献发表数量上已位列世界第一,但在生物技术文献的质量、学术影响力以及国际合作能力方面仍与欧美等发达生物技术国家存在一定差距,接着分析了全球生物技术研究的学科组成、各生物技术分支领域的研究交叉现状,最后分析了目前各生物技术细分领域的热点研究主题。针对当前我国面临的生物技术研究发展问题,我国应当注重研究成果质量,促进各学科间交叉融合,加强国际合作交流,顺应未来生物技术发展热点趋势。     

2005第五届中国国际生物技术展览会暨交流会

为进一步推进生命科学和生物技术的发展,促进中国生物技术企业与国际市场接轨,加速生物科技成果的转化,加强国内外企业技术交流与合作,经科学技术部批准,由中国生物工程学会、中国医药生物技术协会、中国生物技术集团总公司共同举办的“2005第五届中国国际生物技术展览会暨海峡两岸生物技术产业对接交流会”将于2005年8月11-13日在北京举行。展会将邀请国内外生物技术同仁共赴北京参加这一盛会,共同促进我国生物技术产业与国际同行的交流与合作,推动我国生物技术的进步和研发水平的提高。展览会议覆盖生物药品、生物试剂、生物疫苗、生物制品等方面。     

捷克生物科技及产业发展现状与特点

近年来,捷克加快发展高科技、低能耗、低原料消耗的高效能产业,并把生物科技及产业作为重点。捷克建立了多部门协同的生物科技促进和监管体系,着力营造良好的软环境,正在形成以布拉格、布鲁诺、南莫拉维亚为核心的生物技术产业集群。捷克积极参与欧盟框架计划,把国际合作作为推进生物科技跨越发展的着力点,充分发挥地理位置优势和人才资源优势吸引国外投资,力图成为中欧地区最发达的研发外包中心。     

德国：全方位推进生物科技及产业发展

德国是欧洲第一经济大国,对生物科技一贯十分重视,希望生物技术产业成为继汽车、机械制造之后的第三大产业。促进基础研究和产业化开发;注重发挥自身的优势抢占生命科学前沿制高点;实施一系列科技计划全方位推进生物科技创新;着力后备人才培养;依托区域优势和凸显区域特色,多层面促进生物技术产业发展;政府十分重视工业生物技术的发展,大力扶持创新型生物技术企业。     

“一带一路”沿线国家生物技术发展趋势研究

“一带一路”贯穿亚欧非大陆,联结活跃的东亚经济圈和发达的欧洲经济圈,以及中间经济发展潜力巨大的广大腹地国家与地区,“一带一路”战略将对中国未来国内外的政治、经济、文化、科技发展产生重大深远影响。本报告分析了“一带一路”沿线国家的科技发展基础条件,研究了“一带一路”沿线国家在生物技术领域取得的基础研究进展和专利技术研发进展的总体情况,综述了“一带一路”沿线国家生物技术产业发展现状和国际专利布局情况,并针对中国与“一带一路”沿线国家在生物技术领域进一步深化合作互利共赢提出了发展建议。     

我国生物技术基地平台现状与发展建议

生物技术是21世纪以来新一轮科技革命和产业变革的核心,而生物技术基地平台是开展生物技术研究、生产和服务的载体,是生物技术创新体系的重要组成部分。对世界主要发达国家及我国生物技术基地平台的总体规模和建设情况进行梳理分析,并借鉴国外经验,提出改进我国生物技术基地平台建设的政策建议,以供参考。     

Biotechnology in South Africa

Since adopting the National Biotechnology Strategy in 2001, the South African government has established several regional innovation centres and has put in place initiatives to encourage international partnerships that can spur internal development of life science ventures. This strategy seeks to capitalize on the high quality of research carried out in public research institutions and universities but is hampered, somewhat, by the lack of entrepreneurial culture among South African researchers due to, among other reasons, the expenses involved in registering foreign patents. Although private sector development is still relatively embryonic, start-ups are spinning out of universities and pre-existing companies. These represent a vital source of innovations for commercialization in the future, provided that the challenges facing the emerging South African biotechnology industry can be overcome.     

Current state of biotechnology in Turkey

Biotechnology is an interdisciplinary branch of science that encompasses a wide range of subjects like genetics, virology, microbiology, immunology, engineering to develop vaccines, and so on and plays a vital role in health systems, crop and seed management, yield improvement, agriculture, soil management, ecology, animal farming, cellular process, bio statistics, and so on. This article is about activities in medical and pharmaceutical biotechnology, environmental biotechnology, agricultural biotechnology and nanobiotechnology carried out in Turkey. Turkey has made some progress in biotechnology projects for research and development.     

Biotechnology and sustainable development in sub-Saharan Africa

Whether development is defined by the long-standing economic parameter of per capita gross national product (GNP) or by the newly introduced Human Development Index (HDI), which is not based exclusively on per capita GNP, the countries of sub-Saharan Africa rank at or near the bottom of the developing world. Agriculture and agro-based processing are the mainstays of the economies of the majority of these countries. Because of this, and also because many of the diseases endemic in these countries are communicable, the application of modern biotechnology (including genetic engineering, tissue culture and monoclonal antibody technology) and related biotechnologies could play an important part in creating sustainable development in the region. There is, therefore, an urgent need to train more of the region's indigenous citizens, and to equip more laboratories, in modern biotechnology. It is suggested that, in order to accelerate the harnessing of the fruits of biotechnology, more countries in the region should affiliate with the International Centre for Genetic Engineering and Biotechnology (ICGEB). It is further suggested that a regional equivalent of the ICGEB be built and the services of non-governmental biotechnology organizations used.The author is with Nnamdi Azikiwe University, P. M. B. 5025, Awka, Nigeria. Address correspondence to P. M. B. 1457, Enugu, Nigeria     

Opportunities, problems and perspectives for malaria control in sub-Saharan Africa

Environments conducive to high malaria transmission and widespread poverty are at the roots of the 'malaria giant', which affects 46 countries in Africa. The recent interest in and momentum of work on malaria, in endemic countries and the international community, is unprecedented and opens new perspectives for controlling the disease. Significant steps included: (i) the allocation of US$20 million by WHO for accelerated implementation of malaria control in 34 African countries in 1997-98; (ii) the Declaration on Malaria by the Heads of States of the Organization of African Unity and the establishment of the African Initiative for Malaria Control in 1997; (iii) the concomitant mobilisation of the research community in the Multilateral Initiative on Malaria; (iv) the G8 Summit in 1998 in Birmingham asking for higher commitment to malaria control, particularly in Africa; and (v) the Roll Back Malaria initiative set as a WHO priority project in 1998. However, experiences have proved the alarming 'resilience' of the malaria system in Africa, showing devastating consequences when malaria returns to the original levels after intensive control is interrupted. Effective malaria control in Africa requires long-term action, firmly rooted in the social development of the country.     

The socio-economic landscape of biotechnology in Spain. A comparative study using the innovation system concept

Biotechnology is becoming a crucial factor for the innovation strategies of the industrialised countries. Thus, the analysis of the sector is gaining relevance for the identification of the technological strength and potential of a country (or region) in a context of globalisation. A specific national case study may serve for more general comparative analyses. We have selected the case of Spain as illustrative of the complexity and differences existing in Europe. By using the analytical framework of the "national systems of innovation" concept, we have performed a multistep analysis of the biotechnology sector in Spain, focussing first on regions of Madrid and Catalu?a which together account for more than 50% of the sector in Spain. The firms in both regions have followed a common strategy based on diversification and investment in R&D and innovation, so as to be able to compete in an international and competitive environment. There are, however, some interesting differences between the two subsectors; the one from Catalu?a being more based on industrial traditions, and the one from Madrid characterised by the emergence of more specialised firms. The study has been extended to the remainder of Spanish firms for comparative purposes. The case of Spain is illustrative of the divergences existing in the biotechnology sector in Europe. A comparison is made with the structural and organisational characteristics of the biotechnology sector in several European countries. It shows that there is diversity in the pattern of commercialisation between countries and within regions of countries. Understanding these differences may assist the design of appropriate policies to promote the development of biotechnology in Europe.